During the mean observation period of 3.3 years, semaglutide at 2.4 mg per week resulted in a mean weight loss of 9.39% from baseline and a 20% reduction in the risk of MACE (HR 0.80, 95% CI 0.720.90), especially a 28% reduction in the risk of myocardial infarction (HR 0.72, 95% CI 0.610.85), compared with that in the placebo group
Cortisol levels are still elevated above evening baseline, preserving partial circadian receptor advantage while shifting nausea into late afternoon rather than sleep onset
If you have any questions or need further assistance, feel free to book a meeting with our customer support team
In: Comprehensive physiology
Weight Watchers combines access to specialist physicians who prescribe GLP-1s to eligible members, six decades of effective behavior change backed by science, and a community that knows what it takes to succeed
(verified owner) Love this product Rated 5 out of 5 Ashley L